Eden Biosolutions PLC

As of June 30, 2025, Eden Biosolutions PLC carries a market capitalization of 2.00B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eden Biosolutions PLC's next confirmed earnings release is scheduled for December 16, 2026.

As of June 30, 2025, Eden Biosolutions PLC has 533.35M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Eden Biosolutions PLC maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Eden Biosolutions PLC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 2.26, while the 200-day moving average is 3.05.

As of June 30, 2025, Eden Biosolutions PLC holds 184.59M in cash and equivalents against 57.19M in total debt, resulting in a net debt position of -184.59M. Total book value stands at 1.06B, with working capital of 281.68M providing operational flexibility.

Eden Biosolutions PLC's most recent stock split took place on March 2, 2020.